- Home
- CTO vs AUTL Comparison
CTO vs AUTL Comparison
Compare CTO & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$17.78
HOLD
Current Price
$1.66
Company Overview
Basic Information| Metric | CTO | AUTL |
|---|---|---|
| Founded | 1902 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 552.9M | 433.8M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | CTO | AUTL |
|---|---|---|
| Price | $17.78 | $1.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $22.00 | $8.33 |
| AVG Volume (30 Days) | 309.2K | ★ 4.0M |
| Earning Date | 10-28-2025 | 11-12-2025 |
| Dividend Yield | ★ 8.58% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $146,948,000.00 | $51,128,000.00 |
| Revenue This Year | $20.87 | $658.11 |
| Revenue Next Year | $4.29 | $91.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 23.84 | ★ 406.67 |
| 52 Week Low | $15.07 | $1.11 |
| 52 Week High | $20.88 | $2.80 |
Technical Indicators
Market Signals| Indicator | CTO | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 51.34 | 58.01 |
| Support Level | $17.65 | $1.56 |
| Resistance Level | $18.64 | $1.79 |
| Average True Range (ATR) | 0.30 | 0.09 |
| MACD | -0.06 | 0.02 |
| Stochastic Oscillator | 21.80 | 57.58 |
Price Performance
Historical Comparison CTO
AUTL
About CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.